CDP-840

• UNSPSC Description:

  CDP-840 (GR259653X) is a potent, selective and orally active phosphodiesterase IV (PDE IV) inhibitor. CDP-840 inhibits antigen-induced early and late phase bronchoconstriction in conscious squirrel monkeys[1].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cdp-840.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=CC=C([C@@H](C2=CC=CC=C2)CC3=CC=NC=C3)C=C1OC4CCCC4

• Molecular Weight:

  373.49

• References & Citations:

  [1]Jones TR, et al. Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma. Can J Physiol Pharmacol. 1998 Feb;76(2):210-7.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  162542-90-7